<DOC>
	<DOCNO>NCT01188421</DOCNO>
	<brief_summary>This study tramadol agent short-term opioid withdrawal treatment . A randomized , double blind clinical trial compare efficacy safety tramadol clonidine buprenorphine short-term treatment opioid withdrawal conduct . Opioid dependent participant treat residential unit . The primary outcome measure opioid withdrawal symptom .</brief_summary>
	<brief_title>Medications Development Drug Abuse Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>Inclusion/ Participants study male female age 18 60 year . Applicants must opioid dependent base upon Structured Clinical Interview DSMIV ( SCID ) ; addition , must opioid positive urine screening process ( evidence opioid withdrawal ) . They must healthy , significant medical illness ( e.g. , insulin dependent diabetes ) , without significant psychiatric illness ( e.g. , schizophrenia ) besides drug dependence . Females pregnancy test prior study enrollment , find pregnant exclude refer substance abuse program pregnant woman ( Center Addiction Pregnancy ) campus . Volunteers also exclude preadmission hypotension ( due use clonidine study ) . Applicants history seizure ( include substancerelated seizure , alcohol withdrawal relate ) exclude . Alcohol and/or sedative dependence specific exclusionary criterion ( give small risk seizure associate tramadol use ) . Allergies study medication ground exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>